Dose daily

Bhawanipur Global Campus Announces iNATCONPH 2026: A Global Platform for Pharmacy & Allied Health Research

Kolkata: Bhawanipur Global Campus has announced the 16th International Conference - iNATCONPH 2026, a prestigious international scientific conference that will be held on 8–9 October 2026 in Kolkata. The...

Emcure Pharma Receives CDSCO Approval to Launch Poviztra®️ for Fatty Liver Disease Treatment

Emcure Pharmaceuticals Ltd  announced that its co-marketed semaglutide brand, Poviztra®, has received regulatory approval from the Central Drugs...

CDSCO Partners with THSTI to Strengthen Vaccine and Healthcare innovation

The Central Drugs Standard Control Organization (CDSCO), India’s national regulatory authority, and the Translational Health Science and Technology...

EMeRG Launches Hospital Intel Suite™️ to transform MedTech Market

EMeRG, a leading healthcare intelligence provider with over a decade of industry expertise,  announced the launch of Hospital...

CDSCO Issues Final Guidance for Medical Device Software Under MDR 2017

The Central Drugs Standard Control Organisation (CDSCO), functioning under the Directorate General of Health Services, Ministry of Health...

NATCO Gets USFDA Nod for Generic Cancer Drug Olaparib

Alembic Pharmaceuticals Limited announced that its development partner, NATCO Pharma Limited (NATCO), has received tentative approval from the U.S. Food and Drug Administration (USFDA)...

Lupin Earns Great Place To Work® India 2026 Nation Builders Recognition

Lupin Limited (Lupin)  announced that it has been recognized among India's Best Employers in the Nation-Builders Category 2026 by Great Place To Work® India, ranking...

Government Reviews Ayushman Bharat, Plans Next Phase of Healthcare Reforms

The National Health Authority concluded its two-day Chintan Shivir on Ayushman Bharat PM-JAY and the Ayushman Bharat Digital Mission, held July 17–18, 2026, in New Delhi. The gathering brought together health...

Eli Lilly Acquires AtaiBeckley to Accelerate Innovative Depression Treatments

Eli Lilly and Company  and AtaiBeckley Inc.  announced a  agreement for Lilly to acquire AtaiBeckley. The transaction features cash consideration of $6.75 per share,...

AstraZeneca Licenses Novel Lung Cancer Drug Zegfrovy in $1.5B Global Deal

AstraZeneca  announced a exclusive global license agreement with Dizal Pharmaceutical to develop and commercialize Zegfrovy (sunvozertinib), a highly differentiated, oral irreversible EGFR inhibitor designed for targeted lung cancer...

VerGo Pharma Successfully Concludes Unannounced US FDA Inspection with Zero Observations

VerGo Pharma, a leading Contract Research Organization (CRO), announced the successful completion of an unannounced United States Food and Drug Administration (US FDA) inspection at...